Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (16065)	3/8/2006 9:18:51 AM
From: ACAN	Read Replies (2) \| Respond to of 23958

Ray; [GNBT] - not a one trick pony 8:57AM Generex Biotech announces positive preliminary results in a long-term clinical trial of Generex Oral-lyn in juvenile patients with Type-1 diabetes mel (GNBT) 2.02 : Co announces positive preliminary results of a long-term (6 month) clinical trial of Generex Oral-lyn, the co's proprietary oral insulin spray product, in juvenile patients with Type-1 diabetes mellitus. As in the previous study, this new study involves a GNBT Oral-lyn split-dose treatment, i.e. the application of Generex Oral-lyn spray both before and after each meal. Generex believes that this approach offers a new diabetes treatment paradigm by offering improved efficacy and patient compliance resulting in greater metabolic stability thereby better controlling diabetes and reducing the complications associated with it. Treatment of adolescents with Type-1 DM is challenging and GNBT chose to replace the lunchtime dose because it is this dose that is most frequently associated with non-compliance. Allan